User:Natalie Van Ochten/Sandbox 1
From Proteopedia
Dimethylarginine Dimethylaminohydrolase
|
References
- ↑ 1.0 1.1 [Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. American Journal of Physiology. 2007 Dec 1;293(6):3227-3245. PMID:17933965 doi:10.1152/ajpheart.00998.2007
- ↑ [Tran CTL, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atherosclerosis Supplements. 2003 Dec;4(4):33-40. PMID:14664901 doi:10.1016/S1567-5688(03)00032-1]
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 [Frey D, Braun O, Briand C, Vasak M, Grutter MG. Structure of the mammalian NOS regulator dimethylarginine dimethylaminohydrolase: a basis for the design of specific inhibitors. Structure. 2006 May;14(5):901-911. PMID:16698551 doi:10.1016/j.str.2006.03.006]
- ↑ [Janssen W, Pullamsetti SS, Cooke J, Weissmann N, Guenther A, Schermuly RT. The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis. The Journal of Pathology. 2012 Dec 12;229(2):242-249. Epub 2013 Jan. PMID: 23097221 doi:10.1002/path.4127/full]
- ↑ [Humm A, Fritsche E, Mann K, Göhl M, Huber R. Recombinant expression and isolation of human L-arginine:glycine amidinotransferase and identification of its active-site cysteine residue. Biochemical Journal. 1997 March 15;322(3):771-776. PMID: 9148748 doi:10.1042/bj3220771]
- ↑ 6.0 6.1 6.2 [Rasheed M, Richter C, Chisty LT, Kirkpatrick J, Blackledge M, Webb MR, Driscoll PC. Ligand-dependent dynamics of the active site lid in bacterial Dimethyarginine Dimethylaminohydrolase. Biochemistry. 2014 Feb 18;53:1092-1104. PMCID:PMC3945819 doi:10.1021/bi4015924]
- ↑ 7.0 7.1 [Stone EM, Costello AL, Tierney DL, Fast W. Substrate-assisted cysteine deprotonation in the mechanism of Dimethylargininase (DDAH) from Pseudomonas aeruginosa. Biochemistry. 2006 May 2;45(17):5618-5630. PMID:16634643 doi:10.1021/bi052595m]
- ↑ [Pace NJ, Weerpana E. Zinc-binding cysteines: diverse functions and structural motifs. Biomolecules. 2014 June;4(2):419-434. PMCID:4101490 doi:10.3390/biom4020419] <ref></ref>. Cys273 and the water molecules stabilize the Zn(II) ion in a tetrahedral environment. The Zn(II) dissociation constant is 4.2 nM which is consistent with the nanomolar concentrations of Zn(II) in the cells, thus provides more evidence for the regulatory use of Zn(II) by DDAH <ref></ref>.
Inhibitors
L-homocysteine and L-citrulline bind in the active site in the same orientation to create the same intermolecular bonds between it and DDAH <ref></ref>. L-citrulline is a product of DDAH hydrolyzing ADMA and MMA, suggesting DDAH activity creates a negative feedback look on itself. Both molecules enter the active site and cause DDAH to be in its closed lid formation. The αC on either molecule creates three salt bridges with DDAH: two with the guanidine group of Arg144 and one with the guanidine group Arg97. Another salt bridge is formed between the ligand and Asp72. The molecules are stabilized in the active site by H-bonds: αC-amino group of the ligand to main chain carbonyls of Val267 and Leu29. Hydrogen bonds also form between the side chains of Asp78 and Glu77 with the ureido group of L-citrulline.
Like L-homocysteine and L-citrulline, S-nitroso-L-homocysteine binds and the lid region of DDAH is closed. When DDAH reacts with S-nitroso-L-homocysteine, a covalent product, N-thiosulfximide exist in the active site because of its binding to Cys273. N-thiosulfximide is stabilized by several salt bridges and H-bonds. Arg144 and Arg97 stabilize the αC-carbonyl group via salt bridges, and Leu29, Val267, and Asp72 stabilize the Cα-amino group by forming Hydrogen bonds <ref></ref>.
Different Isoforms
DDAH has two main isoforms <ref></ref>. DDAH-1 colocalizes with nNOS (neuronal NOS). This enzyme is found mainly in the brain and kidney of organisms <ref></ref>. DDAH-2 is found in tissues with eNOS (endothelial NOS) <ref></ref>. DDAH-2 localization has been found in the heart, kidney, and placenta <ref></ref>. Additionally, studies show that DDAH-2 is expressed in iNOS containing immune tissues (inducible NOS) <ref></ref>. Both of the isoforms have conserved residues that are involved in the catalytic mechanism of DDAH (Cys, Asp, and His). The differences between the isoforms is in the substrate binding residues and the lid region residues. DDAH-1 has a positively charged lid region while DDAH-2 has negatively charged lid. In total, three salt bridge differ between DDAH-1 and DDAH-2 isoforms. Researchers can take advantage of the fact that there are two different isoforms of this enzyme and create drugs that target one isoform over another to control NO levels in specific tissues in the body <ref></ref>.
Medical Relevancy
DDAH works to hydrolyze MMA and ADMA <ref></ref>. Both MMA and ADMA competitively inhibit NO synthesis by inhibiting Nitric Oxide Synthase (NOS). NO is an important signaling and effector molecule in neurotransmission, bacterial defense, and regulation of vascular tone <ref>[Colasanti M, Suzuki H. The dual personality of NO. ScienceDirect. 2000 Jul 1;21(7):249-252. PMID:10979862 doi: 10.1016/S0165-6147(00)01499-1]<ref/>. Because NO is highly toxic, freely diffusible across membranes, and its radical form is fairly reactive, cells must maintain a large control on concentrations by regulating NOS activity and the activity of enzymes such as DDAH that have an indirect effect of the concentration of NO <ref name="rassaf">[Rassaf T, Feelisch M, Kelm M. Circulating NO pool: assessment of nitrite and nitroso species in blood and tissues. Free Rad. Biol. Med. 2004 Feb 15;36(4):413-422. PMID:14975444 doi:10.1016/j.freeradbiomed.2003.11.011]<ref/>. An imbalance of NO contributes to several diseases. Low NO levels, potentially caused by low DDAH activity and therefore high MMA and ADMA concentrations, have been implicated with diseases such as uremia, chronic heart failure, atherosclerosis, and hyperhomocysteinemia <ref name="tsao">[Tsao PS, Cooke JP. Endothelial alterations in hypercholesterolemia: more than simply vasodilator dysfunction. Journal of Cardiovascular Pharmacology. 1998;32(3):48-53. PMID:9883748]<ref/>. High levels of NO have been involved with diseases such as septic shock, migraine, inflammation, and neurodegenerative disorders <ref name="vallance">[Vallance P, Leiper J. Blocking NO synthesis: how, where and why? Nat. Rev. Drug Discov. 2002 Dec;1(12):939-950. PMD:12461516 doi:10.1038/nrd960]<ref/>. Because of the effects on NO levels and known inhibitors to DDAH, regulation of DDAH may be an effective way to regulate NO levels therefore treating the diseases <ref name="frey" />.
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
</li></ol></ref>